US President Trump has exempted India's pharmaceuticals from new reciprocal tariffs, benefiting the major export industry. This exemption highlights the significance of India's cost-effective generic medicines in US healthcare. The White House noted that removing trade barriers in other sectors could increase US exports by $5.3 billion annually.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pEGlIvA
via IFTTT
No comments:
Post a Comment